Neuroscience Breakthroughs

Redefining Treatments for Neurodegenerative Diseases

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s disease affect millions worldwide, presenting immense challenges for healthcare systems.
These diseases, characterized by progressive neuronal loss and cognitive and motor impairments, currently have limited effective treatments, leaving patients and caregivers with few options. However, advancements in neuroscience are paving the way for breakthroughs in precision medicine, offering new hope in addressing these debilitating conditions.

What Are Neurodegenerative Diseases? – Neurodegenerative diseases encompass a group of disorders characterized by the progressive degeneration or death of nerve cells, leading to cognitive decline, motor dysfunction, and other neurological impairments. Key conditions include:

  • Alzheimer’s Disease (AD): Characterized by amyloid plaques and tau tangles, leading to memory loss and cognitive decline.
  • Parkinson’s Disease (PD): Marked by dopamine neuron loss in the substantia nigra, causing tremors, rigidity, and bradykinesia.
  • Amyotrophic Lateral Sclerosis (ALS): Affects motor neurons, leading to muscle weakness, atrophy, and eventual paralysis.
  • Huntington’s Disease (HD): Caused by genetic mutations, resulting in movement disorders, psychiatric symptoms, and cognitive decline.

Despite differences in their pathology, these diseases share common challenges, including late diagnoses, lack of curative therapies, and limited understanding of their underlying mechanisms.

Historical Context and Development – Over the decades, research in neuroscience has evolved significantly:

  • Early Treatments: In the mid-20th century, symptomatic treatments emerged, such as levodopa for Parkinson’s and cholinesterase inhibitors for Alzheimer’s.
  • The Genetic Era: The discovery of genetic mutations linked to Huntington’s (HTT gene) and familial Alzheimer’s (APP, PSEN1, PSEN2) highlighted hereditary risk factors.
  • Biologic Breakthroughs: Monoclonal antibodies, such as aducanumab and lecanemab, represent a shift toward disease-modifying therapies, aiming to slow or halt disease progression.
  • Current Innovations: Technologies like RNA-based therapies, molecular glues, and CRISPR are transforming the treatment landscape, targeting root causes and enabling personalized medicine.

Recent Industry Momentum and Developments – Neuroscience is experiencing a surge in innovation and investment, reflected in major advancements and high-value partnerships:

  • Biogen and Eisai Collaboration: Their Alzheimer’s drug, lecanemab, received FDA approval for early- stage Alzheimer’s, offering hope for slowing cognitive decline.
  • AbbVie’s Acquisition of Aliada Therapeutics: AbbVie acquired Aliada Therapeutics for $1.4 billion in October 2024, adding ALIA-1758, an experimental antibody therapy targeting amyloid-beta plaques, to its Alzheimer’s treatment portfolio.
  • Takeda’s Partnership with AC Immune: Takeda signed a $2.2 billion deal with AC Immune to develop the Alzheimer’s vaccine ACI-24.060, designed to elicit an immune response against beta-amyloid protein.
  • Eli Lilly’s Tau-Targeted Therapies: Lilly’s experimental drugs targeting tau proteins are in latestage trials, focusing on reducing neurofibrillary tangles.
  • Roche’s Biomarker-Based Precision Medicine: Roche is advancing blood-based biomarkers to identify neurodegenerative diseases earlier, enabling timely interventions.
  • Denali Therapeutics’ BBB-Crossing Technology: Denali’s engineered transport vehicles facilitate the delivery of large biologics across the blood-brain barrier, enhancing drug efficacy.
  • Raya Therapeutic and argenx Collaboration: These companies are leveraging a combinatorial approach in ALS, pairing Raya’s pipeline of small molecules with argenx’s product. Preclinical studies aim to identify the most effective combinations to advance to human trials, offering a novel strategy to address the multifactorial nature of ALS.
  • Emerging Biotechs: Companies like Ionis Pharmaceuticals and Wave Life Sciences are developing RNA-targeted therapies for diseases like Huntington’s and ALS.

Expanding Applications and Technologies – Innovative technologies are reshaping the field of neuroscience, expanding the possibilities for treating neurodegenerative diseases:

  • RNA-Based Therapies: Antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are being used to modulate gene expression, as seen with Ionis’s work on Huntington’s disease.
  • Molecular Glue Degraders: These small molecules selectively target disease-causing proteins for degradation, offering a novel approach for neurodegenerative diseases.
  • Biomarkers for Early Detection: Advances in blood and cerebrospinal fluid biomarkers, such as
    amyloid and tau, enable earlier diagnosis and monitoring of treatment efficacy. These biomarkers are also being incorporated into clinical trials to stratify patients based on disease progression, improving trial outcomes and accelerating drug development.
  • Gene Editing: CRISPR-based approaches are being explored to correct genetic mutations, particularly in conditions like Huntington’s disease.

Challenges and Future Opportunities – While advancements are promising, several challenges remain:

  • Blood-Brain Barrier (BBB): The BBB limits drug delivery to the central nervous system, requiring innovative solutions like Denali’s transport vehicles.
  • Clinical Trial Design: The slow progression of neurodegenerative diseases complicates clinical trial timelines and endpoint measurements.
  • Patient Diversity: Variability in disease presentation and progression necessitates more personalized approaches.

Future opportunities include:

  • Combination Therapies: Combining gene therapies, ASOs, and immunotherapies could yield synergistic benefits. The collaboration between Raya Therapeutic and argenx exemplifies this approach, as they are exploring combinatorial strategies for ALS by pairing small molecules with complementary immunological mechanisms to tackle the multifactorial nature of the disease.
  • Digital Health Solutions: Wearables and AI-driven monitoring tools can track disease progression and improve patient management. For example, AI platforms are being used to analyze data from wearable devices to predict disease milestones in Parkinson’s, enabling proactive treatment adjustments.
  • Regulatory Support: Accelerated approval pathways and adaptive trial designs are expediting drug development.

Conclusion – The landscape of neuroscience and neurodegenerative disease treatment is rapidly evolving. With breakthroughs in biologics, RNA-based therapies, and precision medicine, the future holds promise for addressing unmet needs in this challenging field. By continuing to innovate and collaborate, researchers and industry leaders can unlock new possibilities for treating and managing neurodegenerative diseases, reducing caregiver burden and healthcare costs while offering hope to millions worldwide.

Kindly download the document here.

Author: Dr. Jean Chatellier, PhD
Partner, EVP & Managing Director
KYBORA
Email: jean@kybora.com

About the author.

administrator

20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

TYPE & ENTER: